Replies to post #143908 on Biotech Values

[mcbio]

Sounds like a bunch of BS. I doubt that TMC435 has any particular advantage relative to other PI’s in cirrhotic patients, specifically.

But it begs the question of why the other HCV DAAs, not just PIs, haven't been tested specifically in cirrhotic patients.